Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib (Q33161299)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

23 July 2017

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib (English)

1 reference

Europe PubMed Central

23 July 2017

phase I clinical trial

0 references

author name string

Jonathan W Goldman

1

1 reference

Europe PubMed Central

23 July 2017

Isett Laux

2

1 reference

Europe PubMed Central

23 July 2017

Feng Chai

3

1 reference

Europe PubMed Central

23 July 2017

Ronald E Savage

4

1 reference

Europe PubMed Central

23 July 2017

Dora Ferrari

5

1 reference

Europe PubMed Central

23 July 2017

Edward G Garmey

6

1 reference

Europe PubMed Central

23 July 2017

Richard G Just

7

1 reference

Europe PubMed Central

23 July 2017

Lee S Rosen

8

1 reference

Europe PubMed Central

23 July 2017

language of work or name

0 references

publication date

17 May 2012

1 reference

Europe PubMed Central

23 July 2017

1 reference

Europe PubMed Central

23 July 2017

118

1 reference

Europe PubMed Central

23 July 2017

23

1 reference

Europe PubMed Central

23 July 2017

5903-5911

1 reference

Europe PubMed Central

23 July 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Expression and mutational analysis of MET in human solid cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

21 January 2018

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of c-Met-dependent gene expression by PTEN

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27575

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27575

1 reference

Europe PubMed Central

23 July 2017

1 reference

Europe PubMed Central

23 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33161299&oldid=1982669805"